Cargando…

High concordance of programmed death-ligand 1 expression with immunohistochemistry detection between antibody clones 22C3 and E1L3N in non-small cell lung cancer biopsy samples

BACKGROUND: The detection of programmed death-ligand 1 (PD-L1) expression can enrich for patients who respond to anti-programmed cell death 1 (PD-1)/PD-L1 therapies. Though, for most laboratories, the cost of PD-L1 22C3 pharmDx is prohibitive for widespread use, whereas the laboratory-developed test...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wei, Cao, Ziyang, Gao, Caixia, Huang, Yan, Wu, Chunyan, Zhang, Liping, Hou, Likun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798544/ https://www.ncbi.nlm.nih.gov/pubmed/35117196 http://dx.doi.org/10.21037/tcr-20-101

Ejemplares similares

Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability
por: Ahn, Soomin, et al.
Publicado: (2021)

Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization
por: Kim, Hye Ryun, et al.
Publicado: (2017)

Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer
por: Lee, Seung Eun, et al.
Publicado: (2020)

Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma
por: Parra, Edwin R., et al.
Publicado: (2018)

Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer
por: Xu, Haipeng, et al.
Publicado: (2017)

Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review
por: Sakakibara, Ayako, et al.
Publicado: (2021)

Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience
por: Takeda, Maiko, et al.
Publicado: (2019)

Concordance of Solid Organ Biopsy Diagnoses With Hospital Autopsy and the Contribution of Biopsies to Death
por: Priemer, David S, et al.
Publicado: (2023)

Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma
por: Nishimatsu, Kanako, et al.
Publicado: (2023)

Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma
por: Phillips, Therese, et al.
Publicado: (2018)

Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples
por: Soo, Ross A., et al.
Publicado: (2018)

Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer
por: Holm, Johanna, et al.
Publicado: (2020)

Evaluation of liquid based cytology in detection of EGFR mutation in NSCLC by large samples
por: Dong, Zhengwei, et al.
Publicado: (2020)

Concordance of immunohistochemistry for predictive and prognostic factors in breast cancer between biopsy and surgical excision: a single-centre experience and review of the literature
por: Rossi, Chiara, et al.
Publicado: (2023)

Hysteroscopic endometrial biopsy with immunohistochemistry in the diagnosis of endometritis
por: Zhang, Yan, et al.
Publicado: (2021)

Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma
por: Zajac, Magdalena, et al.
Publicado: (2019)

Concordance between Histology, Immunohistochemistry, and RT-PCR in the Diagnosis of Feline Infectious Peritonitis
por: Stranieri, Angelica, et al.
Publicado: (2020)

PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation
por: Keppens, Cleo, et al.
Publicado: (2020)

Cervical Pre-cancers: Biopsy and Immunohistochemistry
por: Kamal, Meherbano
Publicado: (2022)

Evaluating programmed death‐ligand 1 (PD‐L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study
por: Cerbelli, Bruna, et al.
Publicado: (2021)

Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia
por: Plata, Adriana, et al.
Publicado: (2013)

Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay
por: Danziger, Natalie, et al.
Publicado: (2023)

Concordance of RT-qPCR with immunohistochemistry and its beneficial role in breast cancer subtyping
por: Li, Yilun, et al.
Publicado: (2023)

Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients
por: Wu, Wei, et al.
Publicado: (2020)

Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma
por: Nambirajan, Aruna, et al.
Publicado: (2019)

PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
por: Nesline, Mary K., et al.
Publicado: (2023)

Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
por: Mino-Kenudson, Mari
Publicado: (2016)

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
por: Noske, Aurelia, et al.
Publicado: (2021)

Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

Distribution and concordance of PD-L1 expression by routine 22C3 assays in East-Asian patients with non-small cell lung cancer
por: Fu, Fangqiu, et al.
Publicado: (2022)

Harmonization across programmed death ligand 1 (PD‐L1) assays for lung cancer by immunohistochemistry using noncontact alternating current electric field mixing
por: Matsuo, Tsubasa, et al.
Publicado: (2021)

Diagnostic Utility of TSSC3 and RB1 Immunohistochemistry in Hydatidiform Mole
por: Chia, Wai Kit, et al.
Publicado: (2023)

Cell‐blocks are suitable material for programmed cell death ligand‐1 immunohistochemistry: Comparison of cell‐blocks and matched surgical resection specimens in lung cancer
por: Pak, Min Gyoung, et al.
Publicado: (2019)

Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry
por: Stefanovic, Stefan, et al.
Publicado: (2017)

Mismatch Repair Protein Expression in Endometrial Cancer: Assessing Concordance and Unveiling Pitfalls in Two Different Immunohistochemistry Assays
por: Yoshida, Hiroshi, et al.
Publicado: (2023)

Thrombospondin‐1 induced programmed death‐ligand 1‐mediated immunosuppression by activating the STAT3 pathway in osteosarcoma
por: Liu, Zhuochao, et al.
Publicado: (2021)

Interpretation According to Clone-Specific PD-L1 Cutoffs Reveals Better Concordance in Muscle-Invasive Urothelial Carcinoma
por: Huang, Tzu-Hao, et al.
Publicado: (2021)

Programmed death‐ligand 1 expression on CD22‐specific chimeric antigen receptor‐modified T cells weakens antitumor potential
por: Liu, Jie, et al.
Publicado: (2022)

Grade Group accuracy is improved by extensive prostate biopsy sampling, but unrelated to prostatectomy specimen sampling or use of immunohistochemistry
por: Korpás, Kristóf Levente, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_is1iqgvrnk5dpej3nm973vc0fl